To suppress DDR2 activity in the xenograft mouse model of GC dissemination, we used dasatinib, which is approved for first-line use in patients with chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia30. This evidence concerns the gene DDR2 and chronic myelogenous leukemia, BCR-ABL1 positive.